Propanol

Propanol

SCHEMBL6098189

CCCO.Cl.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Propanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propanol SCHEMBL4269564 1.00
Propanol SCHEMBL1785779 1.00
Propanol SCHEMBL4778557 1.00
Propanol SCHEMBL27472513 1.00
Propanol SCHEMBL28853258 0.95
Propanol SCHEMBL28968828 0.95
Propanol SCHEMBL8369005 0.95 ALDH1A1 (0.50)
Propanol SCHEMBL28381868 0.95
Propanol SCHEMBL3488334 0.95
Propanol SCHEMBL17310395 0.95

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240390338-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES PTC THERAPEUTICS, INC. 2024-11-28 US claimed
CN-118401243-A Methods of treating neurodegenerative diseases PTC医疗公司 2024-07-26 CN claimed
EP-4398987-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES PTC Therapeutics, Inc. (US) 2024-07-17 EP claimed
WO-2023039369-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES PTC THERAPEUTICS, INC. (US) 2023-03-16 WO claimed
CN-115209955-A Compounds for the treatment of familial autonomic nerve dysfunction PTC医疗公司 2022-10-18 CN claimed
WO-2015116394-A1 CLAY STABILIZER AND METHOD OF USE BAKER HUGHES INCORPORATED (US) 2015-08-06 WO claimed
US-20150210913-A1 CLAY STABILIZER AND METHOD OF USE BAKER HUGHES INCORPORATED 2015-07-30 US claimed
US-12384797-B2 Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia PTC THERAPEUTICS, INC. (US) 2025-08-12 US disclosed
US-20240390338-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES PTC THERAPEUTICS, INC. 2024-11-28 US disclosed
US-20240374602-A1 METHODS FOR TREATING NEUROGENERATIVE DISEASES PTC THERAPEUTICS, INC. 2024-11-14 US disclosed
US-20240051968-A1 METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 PTC THERAPEUTICS, INC. (US) 2024-02-15 US disclosed
US-20240043444-A1 METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 PTC THERAPEUTICS, INC. (US) 2024-02-08 US disclosed
CN-115209955-A Compounds for the treatment of familial autonomic nerve dysfunction PTC医疗公司 2022-10-18 CN disclosed
US-20060122215-A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity BAYER PHARMACEUTICALS CORPORATION (US) 2006-06-08 US disclosed
CN-1202096-C 2-aminothiazoline derivatives and their use as no-synthase inhibitors AVENTIS PHARMA SA (FR) 2005-05-18 CN disclosed
CN-1444572-A 2-aminothiazoline derivatives and their use as no-synthase inhibitors AVENTIS PHARMA SA (FR) 2003-09-24 CN disclosed
US-6503282-B1 Composition for coloring keratin fibers based on a developer-coupler combination characterized in that it contains as the coupler 3-(2,4-diaminophenoxy)-1-propanol and as the developer ring and having general formula (I) WELLA AKTIENGESELLSCHAFT (DE) 2003-01-07 US disclosed
US-6388032-B1 SEPARATION BY FILTRATION TEIJIN LIMITED (JP) 2002-05-14 US disclosed
EP-1028128-A1 CYCLOOLEFIN POLYMER REDUCED IN CATALYST RESIDUE CONTENT, USE THEREOF, AND PROCESS FOR PRODUCING THE SAME TEIJIN LIMITED (JP) 2000-08-16 EP disclosed
CN-1099388-A Heteroatom-bearing ligands and metal complexes thereof BRISTOL MYERS SQIBB COMPANY (US) 1995-03-01 CN disclosed